Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study | Zendy

Barbara Jablonowska | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Prevention of recurrent spontaneous abortion by intravenous immunoglobulin: a double-blind placebo-controlled study

Author(s) -

Barbara Jablonowska

Publication year - 1999

Publication title -

human reproduction

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.446

H-Index - 226

eISSN - 1460-2350

pISSN - 0268-1161

DOI - 10.1093/humrep/14.3.838

Subject(s) - placebo , medicine , abortion , pregnancy , live birth , randomized controlled trial , placebo controlled study , obstetrics , saline , double blind , anesthesia , alternative medicine , pathology , biology , genetics

The aim of this study was to evaluate the therapeutic efficacy of intravenous immunoglobulin (IVIG) in the prevention of recurrent spontaneous abortion (RSA). In a double-blind, randomized, placebo-controlled study, 41 women with a history of unexplained recurrent spontaneous abortion were treated with IVIG or saline infusions during pregnancy. The birth of a child was considered a successful outcome. The overall success rate was 77% in the IVIG group compared with 79% in the placebo group. For women with primary RSA the success rates were 82 (IVIG) and 89% (placebo), and for women with secondary RSA the rates were 73 (IVIG) and 70% (placebo). We found no statistically significant difference in treatment results between IVIG and placebo.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research